Vyvanse, Adderall, and Stimulants for Weight: What the Evidence Shows (And Why Most of It Is Off-Label)

Vyvanse (lisdexamfetamine) is the only FDA-approved medication for moderate-to-severe binge-eating disorder (BED) in adults. It is not approved for weight loss as a primary indication. Adderall (mixed amphetamine salts) is FDA-approved for ADHD and narcolepsy. It is also not approved for weight loss. Both are DEA Schedule II controlled substances with cardiovascular and psychiatric warnings. The published BED trial program (McElroy 2015 dose-finding^[1], McElroy 2016 Phase 3 pivotals^[2], Hudson 2017 maintenance^[3], Grilo 2024 continuation^[4]) is real and consistent: Vyvanse 50-70 mg/day produces approximately −5 kg weight loss as a secondary outcome alongside dramatic binge-frequency reductions. But that's the BED population — patients who meet DSM-5 BED criteria, not patients who occasionally overeat. Combining stimulants with a GLP-1 has zero RCT data and additive cardiovascular concerns. Here is the verified evidence.

The McElroy 2015 dose-finding trial

McElroy and colleagues^[1] randomized 259 adults with moderate-to-severe BED to lisdexamfetamine 30, 50, or 70 mg/day or placebo over 11 weeks (3-week titration plus 8-week maintenance). Primary endpoint: log-transformed binge-eating days per week.

• 50 mg dose: significant binge-day reduction vs placebo (p=0.01)
• 70 mg dose: significant binge-day reduction vs placebo (p<0.001)
• 30 mg dose: no significant difference from placebo

4-week binge cessation rates: 50% on 70 mg, 42.2% on 50 mg, vs 21.3% on placebo. Weight loss as a secondary outcome:

• Placebo: −0.1 kg
• 30 mg: −3.1 kg
• 50 mg: −4.9 kg
• 70 mg: −4.9 kg

That weight loss is real and clinically meaningful, but it is the secondary endpoint of a BED trial, not a weight-loss trial. The 50 mg and 70 mg doses became the FDA-approved Vyvanse range for BED.

The 2016 pivotal Phase 3 trials

McElroy 2016^[2] reported the two pivotal Phase 3 trials that supported the FDA approval. n=383 in Study 1 and n=390 in Study 2; 12 weeks total (3-week titration + 9-week maintenance) at 50 or 70 mg/day vs placebo.

• Study 1: Vyvanse reduced binge-eating days by −1.35 days/week more than placebo (p<0.001)
• Study 2: Vyvanse reduced binge-eating days by −1.66 days/week more than placebo (p<0.001)

Most common adverse events (≥10% of patients): dry mouth, insomnia, headache. Mean pulse rate increased 4.4-6.3 bpm in the active arms. The two trials together formed the basis for the FDA's January 30, 2015 approval of Vyvanse for moderate-to-severe BED in adults — the first and only FDA-approved BED medication.

The Hudson 2017 maintenance trial

Hudson 2017^[3] answered the durability question. 418 patients entered a 12-week open-label optimization phase on Vyvanse; 275 completed and were randomized to continue Vyvanse vs switch to placebo for 26 additional weeks of double-blind maintenance.

• BED relapse over 6 months: 3.7% on Vyvanse (5/136 patients) vs 32.1% on placebo (42/131 patients)
• Hazard ratio for relapse: 0.09 (95% CI 0.04-0.23)

The 6-month relapse data are striking. Vyvanse essentially eliminated relapse over 6 months in patients who had responded acutely — a much bigger maintenance effect than the original dose-finding trial would have predicted. This is the strongest single piece of evidence supporting long-term Vyvanse use in BED.

The Grilo 2024 continuation trial

Grilo 2024^[4] in Psychological Medicine (n=61) tested Vyvanse maintenance in patients who had responded to acute LDX with or without CBT. Smaller and more recent than the Hudson trial, with mixed-acute-treatment responders. Outcomes:

• BED relapse: 10.0% on LDX vs 17.9% on placebo (not statistically significant due to small n)
• Weight change at 12-week maintenance: −2.3% LDX vs +2.2% placebo (statistically significant)
• Eating-disorder psychopathology stable on LDX, worsened on placebo

The Grilo trial extends the Hudson 2017 finding into a more recent and slightly more diverse population. Same directional signal: Vyvanse maintains response in BED patients who initially benefited.

BED prevalence and overlap with obesity

Patients sometimes assume BED is rare. It isn't. Two major epidemiology studies bound the prevalence:

Hudson 2007 (NCS-R)^[5] reported from the National Comorbidity Survey Replication (n=9,282 US community respondents):

• Lifetime BED prevalence: 3.5% in women, 2.0% in men (overall ~2.8%)
• Strong association with severe obesity (BMI ≥40)
• Common comorbidity with mood, anxiety, and substance use disorders

Kessler 2013^[6] in 14-country WHO World Mental Health Surveys (n=24,124) reported a lifetime BED prevalence of 1.4% (range 0.8-1.9%) globally — somewhat lower than the US-only Hudson estimate. Both studies emphasized that fewer than half of people with BED ever receive treatment.

BED is a distinct DSM-5 disorder — recurrent binge episodes (≥1 per week for ≥3 months) with marked distress, eating much more rapidly than normal, eating until uncomfortably full, eating large amounts when not physically hungry, eating alone due to embarrassment, and feelings of disgust or guilt afterward. It is not the same as “I sometimes overeat” and it requires a clinical diagnosis. Vyvanse is approved for the diagnosis, not the behavior in isolation.

Vyvanse cardiovascular and psychiatric warnings

The FDA label^[9] for Vyvanse carries a boxed warning for sudden death, myocardial infarction, and stroke. Specific concerns:

• Cardiovascular: mean systolic and diastolic BP increases of approximately 5-10 mmHg, mean resting HR increases of 4-6 bpm at therapeutic BED doses. Avoid in structural cardiac abnormalities, cardiomyopathy, coronary artery disease, and uncontrolled hypertension.
• Psychiatric: psychosis and mania risk, especially at higher doses; aggression, agitation, and paranoid ideation reported in a small proportion. Effects typically resolve 2-6 days after discontinuation.
• Seizure risk: lower than bupropion; ADHD stimulants are actually associated with lower seizure odds in adjusted analyses.
• Abuse and dependence: DEA Schedule II reflects high abuse potential. Lisdexamfetamine is a prodrug (lower immediate-release peak than d-amphetamine or methamphetamine), which somewhat reduces the abuse liability profile vs Adderall.

Adderall and weight loss

Adderall (mixed amphetamine salts) is FDA-approved for ADHD and narcolepsy. It is not approved for weight loss in any population, and any use for weight loss is off-label and not evidence-based. The pediatric ADHD literature documents weight effects (typically −1 to −2 kg in children on long-term stimulant treatment), but no RCT has tested Adderall specifically for weight loss in adults. The DEA explicitly warns that weight lost on stimulants is regained upon cessation and that misuse of prescription stimulants for cosmetic weight loss contributes to stimulant use disorder risk.

Some obesity-medicine specialists prescribe Adderall off-label in patients with comorbid ADHD and obesity, with the rationale that treating the ADHD may improve dietary control and impulse regulation. This is a defensible clinical decision for patients with documented ADHD; it is not an evidence-based weight-loss intervention for non-ADHD patients.

Combining stimulants with a GLP-1

There is no published RCT on combining Vyvanse or Adderall with a GLP-1 receptor agonist. The closest precedent is the phentermine + GLP-1 literature, which we cover in our existing phentermine + GLP-1 article. Theoretical concerns:

• Additive cardiovascular effects. Both drug classes elevate resting heart rate and blood pressure. The combination warrants baseline ECG, baseline BP, and ongoing monitoring.
• Additive appetite suppression. GLP-1s suppress appetite via vagal and CNS GLP-1R activation; stimulants suppress appetite via catecholaminergic mechanisms. The combination can produce excessive nausea, vomiting, gastric dysmotility, or insufficient caloric intake.
• Drug interaction risk. Amphetamines plus GLP-1 agonists on sympathomimetic tone is theoretically concerning, though no PK interaction is documented in the GLP-1 labels.
• Patient selection matters. A patient on Vyvanse for documented BED who develops obesity is a legitimate candidate for adding a GLP-1 with cardiovascular oversight. A patient on Adderall off-label for weight loss who wants to add a GLP-1 is in a much weaker evidence-and-safety position.

Vyvanse cost and access in 2026

Vyvanse went generic on August 25, 2023, when first generic approvals were granted to Actavis Elizabeth, Teva, Aurobindo, and others after the compound patent expired (February 24, 2023) plus a 6-month pediatric exclusivity extension. Prices have dropped 50-85% from the brand peak. As of April 2026, generic lisdexamfetamine is widely available at most US pharmacies.

Adderall, by contrast, has been in active shortage since late 2022 due to API delays, manufacturer discontinuations (Mylan, Zydus discontinued IR tablets), and DEA quota constraints. The DEA increased the 2025 amphetamine APQ from 21.2M to 26.5M grams; the 2026 APQ is 24.2M grams (~14% above original proposal). As of April 2026 the shortage continues with regional and dose-strength variability. This shortage has indirectly increased Vyvanse and other stimulant prescribing as substitutes.

Both drugs are DEA Schedule II controlled substances:

• Written prescription required (no electronic auto-refills in most states)
• No refills allowed; new prescription required each fill
• Some states require triplicate or state-specific forms
• Pharmacy verification of prescriber DEA registration

Off-label vs on-label clarity

For a patient or clinician trying to make sense of all this:

• Vyvanse for diagnosed moderate-severe BED: on-label, evidence-based, FDA-approved. Weight loss is a documented secondary effect.
• Vyvanse for weight loss without BED: off-label, not evidence-based, not recommended.
• Adderall for ADHD: on-label, established. Weight loss is a secondary effect.
• Adderall for weight loss: off-label, not evidence-based, not recommended.
• Phentermine for weight loss: on-label, short-term (12 weeks). See our existing phentermine + GLP-1 article.
• Qsymia (phentermine + topiramate): on-label, chronic weight management. See our Topamax / Qsymia article.

Bottom line

• Vyvanse is FDA-approved for moderate-severe BED in adults, NOT weight loss. Approval based on McElroy 2015 dose-finding, McElroy 2016 pivotal Phase 3 trials, and Hudson 2017 maintenance trial.
• Vyvanse weight effect at 50-70 mg in BED trials: ~−5 kg, secondary outcome.
• BED lifetime prevalence: ~2.8% (Hudson 2007 NCS-R) to 1.4% (Kessler 2013 WHO). Strongly associated with obesity but distinct from occasional overeating.
• Adderall has zero FDA approval for weight loss; off-label use is not evidence-based and not recommended.
• Both drugs are DEA Schedule II with cardiovascular and psychiatric warnings.
• No RCT data on stimulant + GLP-1 combinations. Theoretical additive cardiovascular and appetite-suppression concerns. Cite the phentermine + GLP-1 article as the closest analog.
• Vyvanse generic launched August 25, 2023; substantial price reductions. Adderall remains in shortage as of April 2026.

Related research and tools

• Can you take phentermine with a GLP-1? — the closest stimulant + GLP-1 precedent
• Topamax, Qsymia, and topiramate for weight loss — the FDA-approved phentermine + topiramate combination
• Antidepressants and weight on a GLP-1 — covers bupropion, the closest non-stimulant analog
• Metformin and non-GLP-1 diabetes drugs for weight loss
• GLP-1 drug interaction checker — lookup any concomitant drug
• GLP-1 side effects questions answered — including the cardiovascular signals that overlap with stimulant concerns

Important disclaimer. This article is educational and does not constitute medical advice or a recommendation to use Vyvanse or Adderall for weight loss. Both are DEA Schedule II controlled substances with cardiovascular and psychiatric risks. Diagnosed binge-eating disorder is the only FDA-approved Vyvanse indication for adults; off-label use for weight loss alone is not evidence-based and warrants extreme caution. Decisions about stimulant therapy for any indication should be made with a qualified prescribing clinician (typically psychiatry or specialized obesity medicine) who can document the diagnosis, monitor cardiovascular and psychiatric status, and manage controlled-substance prescribing safely. Every primary source cited here was independently verified against PubMed and FDA on 2026-04-08.